Prognostic Factors for Squamous Cell Cancer of the Anal Canal

Overview

Journal Gastrointest Cancer Res

Date 2009 Mar 5

PMID 19259318

Citations 19

Authors

Prajnan Das

Christopher H Crane

Cathy Eng

Jaffer A Ajani

Affiliations

Soon will be listed here.

Abstract

Radiotherapy with concurrent chemotherapy is the standard of care for patients with nonmetastatic squamous cell anal cancer. Most patients treated with chemoradiotherapy have an excellent prognosis. However, some heterogeneity exists among anal cancer patients in their outcomes. This article reviews some of the clinical factors, treatment-related factors, and biologic factors that affect outcomes in patients with squamous cell anal cancer. The most important prognostic factors are the T and N stages. Some studies have suggested that women have better prognosis than men. Histologic subtypes and grade do not have a clear prognostic role. Response to treatment and duration of radiotherapy are likely to be important prognostic factors. Some molecular markers such as p53, p21, and cyclin A expression may have prognostic significance, but their role needs to be studied further. A better knowledge of prognostic factors could help us develop individualized therapies for patients and select high-risk patients for more aggressive and innovative treatments. A better understanding of molecular biology is required to characterize the inherent heterogeneity of anal cancer and thereby develop optimal therapies.

Citing Articles

Factors Influencing Outcomes and Survival in Anal Cancer.

Temperley H, Mac Curtain B, OSullivan N, Mulhall C, Temperley T, Mehigan B Curr Oncol. 2024; 31(9):5151-5163.

PMID: 39330009 PMC: 11431442. DOI: 10.3390/curroncol31090381.

Ectopic production of beta-hCG in anal cancer: A case report.

Silverwood S, Kohler P, Kier Y Clin Case Rep. 2024; 12(3):e8612.

PMID: 38464575 PMC: 10920316. DOI: 10.1002/ccr3.8612.

Influence of radiation treatment technique (IMRT vs. 3D-RT) on acute toxicity and prognostic factors for survival for anal cancer.

Sauter C, Peeken J, Borm K, Diehl C, Munch S, Combs S Sci Rep. 2022; 12(1):19914.

PMID: 36402828 PMC: 9675840. DOI: 10.1038/s41598-022-24362-8.

Leukocyte subtyping predicts for treatment failure and poor survival in anal squamous cell carcinoma.

Principe D, Cataneo J, Timbers K, Koch R, Valyi-Nagy K, Mellgren A BMC Cancer. 2022; 22(1):697.

PMID: 35751111 PMC: 9229146. DOI: 10.1186/s12885-022-09742-7.

Prognostic factors for patients with anal cancer treated with conformal radiotherapy-a systematic review.

Theophanous S, Samuel R, Lilley J, Henry A, Sebag-Montefiore D, Gilbert A BMC Cancer. 2022; 22(1):607.

PMID: 35659632 PMC: 9164501. DOI: 10.1186/s12885-022-09729-4.

References

. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet. 1996; 348(9034):1049-54. View

Kim J, Sarani B, Orkin B, Young H, White J, Tannebaum I . HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients. Dis Colon Rectum. 2001; 44(10):1496-502. DOI: 10.1007/BF02234605. View

Flam M, John M, Pajak T, Petrelli N, Myerson R, Doggett S . Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996; 14(9):2527-39. DOI: 10.1200/JCO.1996.14.9.2527. View

Oehler-Janne C, Seifert B, Lutolf U, Ciernik I . Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy. Radiat Oncol. 2006; 1:29. PMC: 1570351. DOI: 10.1186/1748-717X-1-29. View

Salmon R, Zafrani B, Labib A, Asselain B, Girodet J . Prognosis of cloacogenic and squamous cancers of the anal canal. Dis Colon Rectum. 1986; 29(5):336-40. DOI: 10.1007/BF02554126. View

Rohatgi P, Swisher S, Correa A, Wu T, Liao Z, Komaki R . Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer. 2005; 104(11):2365-72. DOI: 10.1002/cncr.21439. View

Shepherd N, Scholefield J, Love S, England J, Northover J . Prognostic factors in anal squamous carcinoma: a multivariate analysis of clinical, pathological and flow cytometric parameters in 235 cases. Histopathology. 1990; 16(6):545-55. DOI: 10.1111/j.1365-2559.1990.tb01159.x. View

Meyer A, Meier zu Eissen J, Karstens J, Bremer M . Chemoradiotherapy in patients with anal cancer: impact of length of unplanned treatment interruption on outcome. Acta Oncol. 2006; 45(6):728-35. DOI: 10.1080/02841860600726729. View

Chirieac L, Swisher S, Ajani J, Komaki R, Correa A, Morris J . Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005; 103(7):1347-55. DOI: 10.1002/cncr.20916. View

10.

Trautmann T, Zuger J . Positron Emission Tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal. Mol Imaging Biol. 2005; 7(4):309-13. DOI: 10.1007/s11307-005-0003-6. View

11.

Grabenbauer G, Matzel K, Schneider I, Meyer M, Wittekind C, Matsche B . Sphincter preservation with chemoradiation in anal canal carcinoma: abdominoperineal resection in selected cases?. Dis Colon Rectum. 1998; 41(4):441-50. DOI: 10.1007/BF02235757. View

12.

Constantinou E, Daly W, Fung C, Willett C, Kaufman D, DeLaney T . Time-dose considerations in the treatment of anal cancer. Int J Radiat Oncol Biol Phys. 1997; 39(3):651-7. DOI: 10.1016/s0360-3016(97)00329-5. View

13.

Kauh J, Koshy M, Gunthel C, Joyner M, Landry J, Thomas Jr C . Management of anal cancer in the HIV-positive population. Oncology (Williston Park). 2006; 19(12):1634-8. View

14.

Schlienger M, Krzisch C, Pene F, Marin J, Mauban S, Barthelemy N . Epidermoid carcinoma of the anal canal treatment results and prognostic variables in a series of 242 cases. Int J Radiat Oncol Biol Phys. 1989; 17(6):1141-51. DOI: 10.1016/0360-3016(89)90519-1. View

15.

Sischy B, Doggett R, Krall J, Taylor D, Sause W, Lipsett J . Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study no. 8314. J Natl Cancer Inst. 1989; 81(11):850-6. DOI: 10.1093/jnci/81.11.850. View

16.

Cotter S, Grigsby P, Siegel B, Dehdashti F, Malyapa R, Fleshman J . FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys. 2006; 65(3):720-5. DOI: 10.1016/j.ijrobp.2006.01.009. View

17.

Janjan N, Abbruzzese J, Pazdur R, Khoo V, Cleary K, Dubrow R . Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. Radiother Oncol. 1999; 51(2):153-60. DOI: 10.1016/s0167-8140(99)00054-7. View

18.

Peiffert D, Bey P, Pernot M, Guillemin F, Luporsi E, Hoffstetter S . Conservative treatment by irradiation of epidermoid cancers of the anal canal: prognostic factors of tumoral control and complications. Int J Radiat Oncol Biol Phys. 1997; 37(2):313-24. DOI: 10.1016/s0360-3016(96)00493-2. View

19.

Janjan N, Crane C, Feig B, Cleary K, Dubrow R, Curley S . Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol. 2001; 24(2):107-12. DOI: 10.1097/00000421-200104000-00001. View

20.

Ferrigno R, Nakamura R, Novaes P, Pellizzon A, Aparecida Conte Maia M, Fogarolli R . Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. Int J Radiat Oncol Biol Phys. 2005; 61(4):1136-42. DOI: 10.1016/j.ijrobp.2004.07.687. View